Genetic polymorphisms of thiopurine S-methyltrans-ferase in a cohort of patients with systemic autoimmune diseases

Clinical and Experimental Rheumatology

Volumn 27, Issue 2, 2009, Pages 321-324

  Tani, C ^a   Mosca, M ^a,b   Colucci, R ^b   Gori, G ^b   D'Ascanio, A ^a   Ghisu, N ^b   Fornai, M ^b   Paolo, A Di ^b   Blandizzi, C ^b   Tacca, M Del ^b   Bombardieri, S ^a  

^a Rheumatology Unit   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Azathioprine; Drug toxicity; Pharmacogenomics; Systemic autoimmune diseases; TPMT polymorphism

Indexed keywords

ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM ANTAGONIST; COLCHICINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLINIC ACID; FUROSEMIDE; GABAPENTIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE; THYROXINE; TUMOR NECROSIS FACTOR INHIBITOR; VITAMIN D;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; BODY WEIGHT; CAUCASIAN; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EVALUATION; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ERUPTION; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEARTBURN; HEPATOBILIARY DISEASE; HERPES ZOSTER; HUMAN; INTERSTITIAL PNEUMONIA; ITALY; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MEGALOBLASTIC ANEMIA; NAUSEA; NAUSEA AND VOMITING; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATIC DISEASE; SEX RATIO; SKIN DEFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTIMETABOLITES; AUTOIMMUNE DISEASES; AZATHIOPRINE; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHYLTRANSFERASES; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 67249137972     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. EVANS WE, McLEOD HL: Pharmacogenomics-drug disposition, drug targets. and side effects. New Engi J Med 2003; 348: 538-49.
2. DANESI R, MOSCA M, BOGGI U, MOSCA F, DEL TACCA M: Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. Mol Med Today 2000: 6: 475-82.
3. RUBINI M. PADOVAN M, BARICORDI O. FOTINIDI M, GOVONI M. TROTTA F: The c.1298A>C polymorphism in the methylenetetrahydrofolate reductase gene is associated with rheumatoid arthritis susceptibility in Italian patients. Clin Exp Rheumatol 2008; 26: 163.
4. PHILLIPR. LUQMANI R: Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008; 26 (Suppl. 51): 594-S 104.
5. PAONE C, CHIAROLANZA I. CUOMO C et al.: Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for I-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007; 25: 6 13-6.
6. IPPOLITO A, PETRI M: An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol 2008: 26 (Suppl. 51): S72-S79.
7. JAYNE D: Part 3: Newer therapies for ANCA-associated vasculitis. Clin Exp Rheumatol 2007; 25 (Suppl. 44): S77-9.
8. WANG L. WEINSHILBOUM R: Thiopurine S-methyltransferase pharmacogenetics: insight. challenges and future directions. Oncogene 2006: 25: 1629-38.
9. TROTTI A, COLEVAS AD. SETSER A et al.: CTCAE v 3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003: 13: 176-81.
10. AL HADITHY AF, DE BOER NHK. DERIJKS LJJ, ESCHER JC. MULDER CJ. BROUWERS JR: Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendation. Dig Liv Dis 2005; 37: 282-297.
11. ROSSI AM, BIANCHI M, GUARNIERI C. BARALE R. PACIFICI GM: Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol 2001; 57: 5 1-4.
12. COLOMBEL JF, FERRARI N, DEBUYSERE H et al.: Genotypic analysis of thiopurine Smethyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
13. GEARRAY RB, BARCLAY ML: Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005: 20: 1149-57.
14. BLACK AJ. Mc LEOD HL, CAPELL HA et al.: Thiopurine methyltransferase genotype predicts therapy-limiting sesere toxicity from azathioprine. Ann Intern Med 1998: 129: 716-8.
15. OH KT. ANIS AH. BAE SC: Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology 2004: 43: 156-63.
16. PIERIK M. RUTGEERTS P. VLIETINCK R. VARMEIRE S: Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 2006; 12: 3657-67.
17. MARRA CA. ESDAILE JM. ANIS AH: Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheunmatol 2002: 29: 2507-12.
18. NAUGHTON MA. BATTAGLIA F. OBRIEN S. WALPORT MJ. BOTTO M: Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppressinn in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999: 38: 640-4.
19. JUN JB. CRO DY. KANG C. BAE SC: Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005: 23: 873-6.
20. CLUNIE GE LENNARD L: Relesance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology 2004: 43: 13-8.
21. OKADAY. NAKAMURA K. KODAMA T et al.: Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus. Biol Pharmn Bull 2005: 28: 2117-9.
22. COROMINAS H. DOMÈNECH M. LAÌZ A et al.: Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatologm 2003: 42: 40-5.